Lithium carbonate and leukocytosis

Area of Science:

• Psychiatry
• Hematology
• Pharmacology

Background:

• Lithium carbonate is a common treatment for psychiatric disorders.
• Changes in white blood cell (WBC) counts can occur during medical treatments.
• Understanding drug-induced hematological effects is crucial for patient safety.

Purpose of the Study:

• To investigate the effect of lithium carbonate on white blood cell (WBC) counts in hospitalized adult psychiatric patients.
• To determine if observed changes in WBC counts are related to lithium therapy.

Main Methods:

• Retrospective analysis of WBC counts from 37 hospitalized adult psychiatric patients undergoing lithium carbonate treatment.
• Patients were divided into two groups: those with pre- and post-treatment WBC counts (Group 1) and those with only post-treatment counts (Group 2).
• Statistical analysis was performed to compare WBC counts before and after lithium therapy and against normal ranges.

Main Results:

• A statistically significant increase (p < 0.001) in WBC counts was observed in Group 1 patients after lithium therapy, with a mean increase of 2,237 cells/cu mm.
• Group 2 patients exhibited a mean WBC count of 11,950 +/- 4,028 cells/cu mm, which is above the normal range for peripheral blood leukocytes.
• The majority of patients showed an increase in circulating leukocytes, indicating a consistent effect of lithium carbonate.

Conclusions:

• Lithium carbonate treatment is associated with drug-related leukocytosis in psychiatric patients.
• The observed increase in WBC count does not appear to be dependent on the dosage or blood concentration of lithium.
• Further research may be warranted to elucidate the mechanisms behind lithium-induced leukocytosis.